Literature DB >> 6716274

Discrimination between the venous equilibrium and sinusoidal models of hepatic drug elimination in the isolated perfused rat liver by perturbation of propranolol protein binding.

D B Jones, D J Morgan, G W Mihaly, L K Webster, R A Smallwood.   

Abstract

To discriminate between two widely used models of hepatic drug elimination, the venous equilibrium and sinusoidal models, we examined the effect of altering perfusate protein binding on the hepatic elimination of the highly cleared drug, propranolol, by the isolated perfused rat liver. We investigated specifically the relationship between the unbound fraction of drug perfusing the liver and the steady-state unbound drug concentration in hepatic venous effluent (i.e., in the perfusate reservoir) after a constant infusion of drug (1.37 mg/hr) into the portal vein. Each rat liver (n = 21) was perfused over 60 min at one of seven different protein concentrations, such that the unbound fraction of propranolol in the portal venous perfusate was varied from 0.1 to 0.65. The unbound steady-state propranolol concentration in the hepatic venous effluent remained unchanged, despite an almost 7-fold increase in the free fraction of propranolol perfusing the liver. The data conform precisely to the predictions of the venous equilibrium model and are incompatible with the sinusoidal model, which predicts a 100-fold decrease in unbound reservoir concentration. This study therefore establishes that the apparently "unphysiological" venous equilibrium model represents a valid description of the hepatic elimination of this high clearance compound.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6716274

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination.

Authors:  C H Chou; L Aarons; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

2.  Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate.

Authors:  M S Roberts; S Fraser; A Wagner; L McLeod
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

3.  Availability predictions by hepatic elimination models for Michaelis-Menten kinetics.

Authors:  M S Roberts; J D Donaldson; D Jackett
Journal:  J Pharmacokinet Biopharm       Date:  1989-12

4.  A comparative investigation of hepatic clearance models: predictions of metabolite formation and elimination.

Authors:  M V St-Pierre; P I Lee; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1992-04

5.  Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs.

Authors:  L P Rivory; M S Roberts; S M Pond
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

6.  Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 2. Effect of pharmacological agents, retrograde perfusions, and enzyme inhibition on evans blue, sucrose, water, and taurocholate.

Authors:  M S Roberts; S Fraser; A Wagner; L McLeod
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

7.  On the degree of solute mixing in liver models of drug elimination.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

8.  Metabolite mean transit times in the liver as predicted by various models of hepatic elimination.

Authors:  G D Mellick; Y G Anissimov; A J Bracken; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

Review 9.  The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.

Authors:  D K Meijer; P Van der Sluijs
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

10.  A dispersion model of hepatic elimination: 2. Steady-state considerations--influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity.

Authors:  M S Roberts; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1986-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.